Publication | Closed Access

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial

First-line TherapyBreast OncologyOncologyGemcitabine Versus PaclitaxelPharmacologyBreast CancerAnti-cancer AgentCancer TreatmentMedicinePhase 3